The viability of vertebrate cells depends on a complex signaling interplay between survival factors and celldeath effectors. Subtle changes in the equilibrium between these regulators can result in abnormal cell proliferation or cell death, leading to various pathological manifestations [1, 2]. Death-associated protein kinase (DAPK) is a multidomain calcium/calmodulin (CaM)-dependent Ser/Thr protein kinase with an important role in apoptosis regulation and tumor suppression [3-6]. The molecular signaling mechanisms regulating this kinase, however, remain unclear. Here, we show that DAPK is phosphorylated upon activation of the Ras-extracellular signal-regulated kinase (ERK) pathway [7] . This correlates with the suppression of the apoptotic activity of DAPK. We demonstrate that DAPK is a novel target of p90 ribosomal S6 kinases (RSK) 1 and 2, downstream effectors of ERK1/2 [8-11]. Using mass spectrometry, we identified Ser-289 as a novel phosphorylation site in DAPK, which is regulated by RSK. Mutation of Ser-289 to alanine results in a DAPK mutant with enhanced apoptotic activity, whereas the phosphomimetic mutation (Ser289Glu) attenuates its apoptotic activity. Our results suggest that RSK-mediated phosphorylation of DAPK is a unique mechanism for suppressing the proapoptotic function of this death kinase in healthy cells as well as Ras/Raf-transformed cells.
In HEK293E cells, overexpression of DAPK results in extensive apoptotic cell death by 24 hr posttransfection ( Figure 1A , compare bar 1 to bar 5). We sought to determine whether activation of cell-survival pathways in DAPK-expressing cells would provide protection against cell death [7, 12] . The Ras-MAPK (mitogen-activated protein kinase) pathway has been shown to promote cell-survival signaling and is the major mechanism for protection against cell death in certain cell types [7] . Interestingly, we found that treatment of cells with the phorbol ester PMA, which activates the Ras-MAPK pathway but not the PI3K-Akt/PKB pathway, antagonized the death-inducing activity of DAPK, leading to increased survival of DAPK-expressing cells ( Figure  1A ). In contrast, when cells were pretreated with the MEK1/2/5 inhibitor U0126, there was enhanced cell *Correspondence: john_blenis@hms.harvard.edu death and PMA did not attenuate the apoptotic effects of DAPK ( Figure 1A) . We considered the possibility that DAPK was inhibited upon phosphorylation by kinases downstream of MEK in this cascade. Because RSK is a potential cell-survival kinase in this cascade [7] , we used an antibody that recognizes the consensus phosphorylation motif, RXRXXpS/T, which recognizes substrates of several basophilic kinases within the AGC family such as RSK, as well as Akt and ribosomal S6 kinase 1 (S6K1) [13] [14] [15] . Using this antibody, we found that PMA stimulated basophilic site phosphorylation of endogenous (see Figure S1A in the Supplemental Data available with this article online) and overexpressed DAPK ( Figure 1B) . Importantly, we also found that phosphorylation of DAPK, similar to the death-protecting effect of PMA, was completely inhibited by U0126. These results indicated that activation of the Ras-MAPK cascade induced MEK-dependent phosphorylation of DAPK, suggesting that this cascade may inhibit apoptosis by directly regulating DAPK phosphorylation.
To further characterize the pathways leading to DAPK phosphorylation, we stimulated cells with different agonists and analyzed them for DAPK phosphorylation. Stimulation of cells with either PMA or EGF led to robust activation of the ERK-MAPK pathway and DAPK phosphorylation, whereas incubation of cells with insulin, a PI3-kinase agonist, or with anisomycin, a p38-MAPK agonist, did not alter DAPK phosphorylation ( Figure 1C ). Consistent with these results, PMA-induced phosphorylation of DAPK was completely inhibited by U0126 and BIM (bisindolylmaleimide I), indicating that PMA-stimulated DAPK phosphorylation requires MEK and protein kinase C (PKC), respectively. Furthermore, treatment of cells with wortmannin or rapamycin did not alter DAPK phosphorylation, again demonstrating that the PI3-kinase and mTOR pathways are not necessary for these effects ( Figure S1B ). These data suggests that basophilic kinases regulated by the Ras-MAPK pathway are likely involved in DAPK phosphorylation stimulated by PMA and exclude the involvement of other basophilic kinases including Akt, MSK, and S6K.
To further establish the link between Ras signaling and DAPK phosphorylation, we transfected activated versions of Ras (Ras61L), B-Raf (ER-⌬B-Raf), and MEK (MEK-DD) in cells overexpressing DAPK [16, 17] . These oncogenic signaling proteins potently stimulated growth-factor-and phorbol-ester-independent phosphorylation of DAPK ( Figures 1D and 1E) , suggesting that activation of the Ras-MAPK pathway is sufficient to induce DAPK phosphorylation. Finally, we also observed a reduction in DAPK phosphorylation by PMA by partially knocking down endogenous ERK1/2 (Figure S1C) .
The Ras-MAPK pathway activates the RSK family of proteins in response to growth factors and phorbol esters [8] . Activation of RSK coincides with oncogenic transformation [18] , stimulation of G0/G1 transition [19] [20] [21] , and differentiation of PC12 cells [10] . To determine whether RSK could directly phosphorylate DAPK, we performed an in vitro kinase assay with immunoprecipitated DAPK as substrate. The kinase-inactive DAPK (K42A) was used in this experiment to avoid potential 32 P incorporation through possible DAPK autophosphorylation. DAPK was phosphorylated in vitro by activated RSK1 but not by kinase-inactive RSK1, and RSK-dependent DAPK phosphorylation was inhibited by UO126 (Figure 2A ). To test whether RSK can phosphorylate DAPK in vivo, we coexpressed RSK1 with DAPK in HEK293E cells, which resulted in an 8-fold increase in phosphorylation of DAPK upon stimulation with PMA ( Figure 2B) . Moreover, when coexpressed in cells, kinase-inactive RSK1 did not increase DAPK phosphorylation ( Figure 2B ), suggesting that RSK kinase activity is necessary for phosphorylation of DAPK in cells. There was no effect on DAPK phosphorylation when cells were coexpressed with either Akt or MSK2 ( Figure  S2A ). We also observed that both RSK1 and RSK2 were able to phosphorylate DAPK in HEK293E cells ( Figure  S2B ). Interestingly, a constitutively active form of RSK1 (myrRSK1) [8, 22] , when coexpressed with DAPK, strongly induced DAPK phosphorylation ( Figure 2C) . RSK has been shown to be associated with most of its physiological targets [8] . In the present study, we also observed a stimulation-independent interaction of RSK1 with DAPK ( Figure 2D ). To further validate the role of RSK1/2 in DAPK phosphorylation, we eliminated RSK1/2 expression by partially knocking down endogenous RSK1/2 with siRNA. This resulted in a dramatic decrease in DAPK phosphorylation ( Figure 2E ), indicating that both RSK1 and RSK2 play a role in regulating DAPK phosphorylation. Taken together, these results demonstrate that DAPK is a specific target of RSK.
To identify potential RSK phosphorylation sites in DAPK, tryptic peptides of immunopurified DAPK were subjected to LC-MS/MS/MS analysis with a Fourier transform ion cyclotron resonance (FTICR)/ion trap hybrid mass spectrometer ( Figure 3A) . One tryptic phosphopeptide, found uniquely from PMA-treated cells, showed phosphorylation at Ser-289, a residue lying in a minimal target site for RSK. The high-mass accuracy measurement of this phosphopeptide in the FTICR cell (0.9 ppm) and the MS 3 spectrum of the precursor ion less a neutral loss of phosphoric acid permitted an unequivocal identification of the phosphorylation site (Figure 3B) . The identified phosphorylation site does not lie in a perfect RXRXXS/T consensus sequence reported to be recognized by the anti-RXRXXpS/T motif antibody. Therefore, to determine whether this phosphospecific antibody was indeed recognizing DAPK phosphorylated at Ser-289, we generated a phosphorylation-deficient mutant of DAPK (Ser289Ala). Mutation of Ser-289 to alanine almost completely inhibited PMA-induced DAPK phosphorylation (Figure 3C ), indicating that Ser-289 is the predominant site phosphorylated by the activation of Ras-MAPK pathway. Thus, the anti-RXRXXpS/ T motif antibody appears to recognize similar, but not identical, basophilic sequences. We also generated point mutations of several other RXRXXS/T sites in DAPK, but we did not see any effect on PMA-induced phosphorylation (data not shown). Moreover, we did not detect these sites in the MS analysis, notwithstanding our conducting of a targeted approach as done for Ser-289.
To address the physiological relevance of the RSK- [23] . These contradictory findings may be attributed in part to the cell-type differences. In addition, it is well established that very potent activation of Ras can lead to cell death [24] , although the molecular basis for this remains unclear. Future work will undoubtedly reveal how this molecular switch between survival and death is made by the ERK/RSK/ DAPK protein-kinase module.
Our results support a model wherein activation of 
